Letters Section Editor: Robert M. Golub, MD, Senior Editor.
To the Editor: Dr Vogel and colleagues1 reported the results of the Study of Tamoxifen and Raloxifene (STAR) P-2 trial. I was disappointed that in the accompanying Editorial, Drs Gradishar and Cella2 did not comment on the role of the effects of raloxifene on the breast when choosing an agent to treat a patient with osteoporosis or osteopenia who has breast cancer risk factors. The MORE3 and CORE4 trials, while not performed on a group at high risk for breast cancer, showed a significant reduction in new-onset breast cancer. This may not be widely known because raloxifene is not approved for any breast indication.
Goldstein SR. Raloxifene vs Tamoxifen. JAMA. 2007;297(3):263-264. doi:10.1001/jama.297.3.263-b